Greater simplicity and reliability in the determination of amino acid sequences
Shimadzu, a worldwide leading manufacturer of analytical instrumentation, provides perfect fit solutions in hardware and software components. For amino acid sequences, the PPSQ 51A / 53 A protein sequencer series and the LabSolutions PPSQ software create user benefits leading to greater simplicity and reliability combined with FDA compliance.
PPSQ protein sequencers separate PTH-amino acids isocratically. This improves baseline stability and allows high-sensitivity analysis of PTH-amino acids. Isocratic sequence analysis provides more stable retention times, so peaks detected in previous cycles can be cancelled using subtraction chromatogram processing, making it easier to identify sequences.
LabSolutions PPSQ software provides compliance with FDA 21 CFR Part 11 guidelines and enables compliance with the security, user management and audit trail requirements specified by FDA 21 CFR Part 11. Specialized protein sequencer software makes it simple to perform reprocessing of chromatograms, overlay of multiple chromatograms and automatic estimation of amino acid sequences, which are required for sequence analysis.
Contact Details:
Shimadzu Europa GmbH
Albert-Hahn-Strasse 6-10
47269 Duisburg, Germany
phone: +49 (0) 203-7687-0
shimadzu@shimadzu.euwww.shimadzu.eu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
